Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$16.31 USD

16.31
1,660,612

-0.28 (-1.69%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $16.33 +0.02 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More

by Zacks Equity Research

Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

by Zacks Equity Research

Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.

Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down

by Zacks Equity Research

Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.

Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

by Zacks Equity Research

Pharvaris (PHVS) rises 6% after the FDA lifts the clinical hold on the investigational candidate, deucrictibant, for the prophylactic treatment of HAE attacks.

Here's Why You Should Add Xenon (XENE) to Your Portfolio Now

by Zacks Equity Research

Xenon's (XENE) late-stage studies in epilepsy are progressing well. The company is also gearing up to initiate a late-stage study for the MDD indication in 2024.

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

by Zacks Equity Research

Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.

Hologic (HOLX) Q1 Earnings Might Rise on Breast Health Growth

by Zacks Equity Research

Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

by Zacks Equity Research

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.

Roche's (RHHBY) Tecentriq Subcutaneous Gets Approval in the EU

by Zacks Equity Research

Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

by Zacks Equity Research

Thermo Fisher (TMO) will likely gain from strong Analytical Instrument business performance and the latest strategic pacts.

What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?

by Zacks Equity Research

Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.

Adicet (ACET) Stock Rallies 130% in a Month: Here's Why

by Zacks Equity Research

Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.

Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why

by Zacks Equity Research

After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

by Zacks Equity Research

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

by Zacks Equity Research

Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.

Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal

by Zacks Equity Research

Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.

Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues

by Zacks Equity Research

Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.

Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues

by Zacks Equity Research

Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.

Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs

by Zacks Equity Research

Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.

Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies

by Zacks Equity Research

Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.

Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong

by Zacks Equity Research

Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.